Quidel

News Release

Printer Friendly Version View printer-friendly version
<< Back
Physicians More Appropriately Prescribe Treatment after Rapid Flu and RSV Testing of Pediatric Patients

QuickVue(R) Influenza and RSV Tests by Quidel Used in Study During

2005-06 Season

SAN DIEGO--(BUSINESS WIRE)--Oct. 8, 2007--Quidel Corporation (NASDAQ:QDEL), a leading provider of rapid point-of-care (POC) diagnostic tests, announced today that a large study released during the poster sessions at the Infectious Diseases Society of America 45th Annual Meeting (October 5, San Diego) supported rapid diagnostic testing for influenza and RSV in order to prescribe appropriate treatment for pediatric patients with influenza-like illnesses (ILI).

The study, entitled "Benefits of Rapid Influenza and Respiratory Syncytial Virus Testing in Pediatric Clinic Patients," was conducted by Dr. Aleta Bonner, MD, DVM, assistant clinical professor, emergency medicine, Texas A&M University Health Science Center, College of Medicine and UTMB, Dept. of Pediatrics, and her colleagues during the winter of 2005-2006. A total of 876 ILI pediatric patients who were tested for influenza and RSV using the QuickVue brand tests were enrolled in the study. The physicians participating in the study were divided into two groups: one group was the physician-aware group (they received the results of the rapid test before prescribing treatment); and the other was the physician- unaware group. The physician-aware group, who had patients who tested flu positive and RSV negative, was four times more likely to prescribe antiviral treatment for children with influenza than were the physicians in the unaware group (53% vs. 12.2% (P less than 0.0001))(1). In addition, the physician-aware group was significantly less likely (p less than 0.006) to prescribe antibiotics for children with influenza than were the physicians in the unaware group. Patients who tested flu negative, but RSV positive were also significantly less likely to receive antibiotics (p less than 0.003).

"With the concern over appropriate treatment of influenza and the inappropriate use of antibiotics, this study is another example of how the deployment of a rapid test for flu can be beneficial to the patient and the healthcare facility," said Caren Mason, president and CEO of Quidel. "Our efforts to raise awareness of this important tool to guide appropriate treatment are ongoing through clinical studies, medical education and other efforts which we label QVB(TM) (Quidel Value Build)."

According to the Centers for Disease Control (CDC), influenza is responsible for about 36,000 deaths and more than 200,000 hospitalizations in the U.S. each year.

About Quidel Corp.

Quidel Corporation serves to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point of care (POC) in infectious diseases and reproductive health. Marketed under the leading brand name of QuickVue(R), Quidel's portfolio of products currently includes tests that aid in the diagnosis of several disease or condition states, including influenza, respiratory syncytial virus, Fecal Occult Blood, Strep A, pregnancy, bacterial vaginosis, H. pylori and Chlamydia. Quidel's products are sold to healthcare professionals with a focus on the physician office lab and acute care markets through leading medical distribution partners on a worldwide basis. Quidel's Specialty Products Group (SPG) develops research products in the fields of oncology and bone health with potential future point-of-care applications. By building value in rapid diagnostic tests, Quidel provides leadership to the industry and among healthcare professionals allowing for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care and other outpatient settings where rapid testing and treatment has an impact on clinical outcomes and provides an economic benefit. For more information, visit www.quidel.com, www.flutest.com, or www.colorectal-test.com.

This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actual results and performance may differ materially. As such no forward-looking statement can be guaranteed. Differences in actual results and performance may arise as a result of a number of factors including, without limitation, seasonality, the length and severity of cold and flu seasons, uncertainty surrounding the detection of novel influenza viruses involving human specimens, adverse changes in the competitive and economic conditions in domestic and international markets, actions of our major distributors, technological changes and uncertainty with research and technology development, including any future molecular-based technology, the reimbursement system currently in place and future changes to that system, manufacturing and production delays or difficulties, adverse actions or delays in product reviews by the U.S. Food and Drug Administration (the "FDA"), intellectual property, product liability, environmental or other litigation, required patent license fee payments not currently reflected in our costs, potential inadequacy of booked reserves and possible impairment of goodwill, and lower-than-anticipated sales or market penetration of our new products. Forward-looking statements typically are identified by the use of terms such as "may," "will," "should," "might," "expect," "anticipate," "estimate," and similar words, although some forward-looking statements are expressed differently. The risks described under "Risk Factors" in reports and registration statements that we file with the SEC from time to time should be carefully considered. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this press release. We undertake no obligation to publicly release the results of any revision or update of the forward-looking statements.

(1) Poster presented October 5, 2007, IDSA, San Diego, CA on file at Quidel Corporation.

CONTACT: Quidel Corporation 858-552-7962
or
Lippert/Heilshorn & Associates
Don Markley, 310-691-7100

SOURCE: Quidel Corporation